http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Final Results of NAPOLI-1 Study Confirm Overall Survival and Progression-Free Survival Benefit for the ONIVYDE® Regimen for Patients with Metastatic Pancreatic Cancer
-
Merrimack Pharma (MACK) Will Present Phase 3 NAPOLI-1 Study Data at ESMO 2016
-
Merrimack to Present Final Results of Phase 3 NAPOLI-1 Study at the European Society for Medical Oncology 2016 Congress
-
Merrimack Reports Second Quarter 2016 Financial Results
-
Merrimack's (MACK) ONIVYDE Receives Positive CHMP Opinion
-
Merrimack Announces ONIVYDE® Regimen Receives Positive CHMP Opinion in European Union
-
Merrimack Announces Timing of Second Quarter 2016 Investor Conference Call
-
Merrimack Pharma's (MACK) Seribantumab Granted FDA Fast Track Designation for NSCLC
-
FDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer
-
NAPOLI-1 Data Demonstrates ONIVYDE® Regimen Maintains Quality of Life While Improving Overall Survival in Patients with Metastatic Pancreatic Cancer
-
Merrimack Pharma (MACK) to Present Phase 3 NAPOLI-1 Data Analysis at ESMO
-
Merrimack to Present New Analyses of Phase 3 NAPOLI-1 Data at the ESMO 18th World Congress on Gastrointestinal Cancer
-
Merrimack Pharma (MACK) Announces Presentation of Positive MM-151 Phase 1 Data in Solid Tumors at ASCO
-
Final Analysis of First-in-Human Phase 1 Study of MM-151 Shows Positive Clinical Activity in Multiple Solid Tumor Types, Including Colorectal Cancer
-
Merrimack Announces a Leading-edge Biomarker-Selected, Multi-Arm Basket Trial that Matches Patients with Most Appropriate Combination Regimens
-
Merrimack and Baxalta Announce Initiation of Phase 1 Study of MM-151 in Combination with the ONIVYDE® (irinotecan liposome injection) Regimen in Metastatic Colorectal Cancer
-
Merrimack Pharma (MACK) to Present on Extensive Oncology Pipeline at ASCO
-
Merrimack to Present on Extensive Oncology Pipeline at the 2016 American Society of Clinical Oncology Annual Meeting
-
Merrimack (MACK) Presents Analysis from Seribantumab Phase 2 Breast Cancer Study at AACR
-
Merrimack Presents Expanded Analysis from Seribantumab (MM-121) Phase 2 Breast Cancer Study at the AACR Precision Medicine Series
-
Merrimack Reports First Quarter 2016 Financial Results
-
Merrimack Pharma (MACK) to Present Positive MM-310 Preclinical Data at AACR 2016
-
Merrimack Unveils its Latest Antibody Directed Nanotherapeutic, MM-310, at the 2016 AACR Annual Meeting
-
Merrimack Announces Timing of First Quarter 2016 Investor Conference Call
-
Merrimack Pharma (MACK), Leica Biosystems Announce Pact to Develop Heregulin Companion Diagnostic for Seribantumab
-
Leica Biosystems and Merrimack Pharmaceuticals to Collaborate on Development of a Heregulin Companion Diagnostic for Seribantumab
-
Merrimack Announces Inclusion of ONIVYDE® (irinotecan liposome injection) as a Category 1 Treatment Option in the 2016 NCCN Guidelines for Pancreatic Adenocarcinoma
-
Merrimack (MACK) Announces Presentations Related to Oncology Pipeline at AACR
-
Merrimack to Present on Multiple Oncology Programs at the 2016 American Association for Cancer Research Annual Meeting
-
Merrimack Reports Fourth Quarter 2015 Financial Results
-
Merrimack Announces Timing of Fourth Quarter 2015 Investor Conference Call
-
Merrimack Pharma (MACK) Issues Positive OS Update from Phase 3 NAPOLI-1 Study (BXLT)
-
Updated Data Shows ONIVYDE® (irinotecan liposome injection) Combination Regimen Increased One Year Survival by 63% in Patients with Metastatic Pancreatic Cancer
-
Merrimack to Present Updated Overall Survival Analysis of Phase 3 NAPOLI-1 Study of ONIVYDE™ (irinotecan liposome injection) at the American Society of Clinical Oncology (ASCO) 2016 Gastrointestinal
-
Merrimack to Present at the 34th Annual J.P. Morgan Healthcare Conference
-
Merrimack Pharma (MACK) Amends Ongoing Phase 2 Study of MM-121 in NSCLC
-
Merrimack Amends MM-121 Phase 2 Clinical Study in Heregulin-Positive Non-Small Cell Lung Cancer to Support Potential Registration
-
Merrimack Announces Presentations at the 2015 San Antonio Breast Cancer Symposium
-
Merrimack and Baxalta Announce Publication of the ONIVYDE™ (irinotecan liposome injection) NAPOLI-1 Study in The Lancet
-
Merrimack Reports Third Quarter 2015 Financial Results
-
Merrimack Pharmaceuticals (Nasdaq: MACK) to Ring The Nasdaq Stock Market Opening Bell
-
Merrimack Pharmaceuticals (Nasdaq: MACK) to Ring The Nasdaq Stock Market Opening Bell
-
Merrimack to Present Research on Multiple Programs at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
-
Merrimack Announces Timing of Third Quarter 2015 Investor Conference Call
-
Merrimack and Baxalta Announce Enrollment of First Patient in Phase 2 Study of ONIVYDE™ (irinotecan liposome injection) in Previously Untreated Front-line Metastatic Pancreatic Cancer
-
Merrimack Announces U.S. FDA Approval of ONIVYDE™ (irinotecan liposome injection) for the Treatment of Patients with Metastatic Pancreatic Cancer
-
Merrimack Debuts New Website
-
Merrimack Pharmaceuticals Reports Second Quarter 2015 Financial Results
-
Merrimack Pharmaceuticals Names Dr. Yasir Al-Wakeel as Chief Financial Officer and Head of Corporate Development
-
Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call
